Insulet Corporation vs Boston Scientific Corporation
A head-to-head of Insulet Corporation (PODD) and Boston Scientific Corporation (BSX) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | PODD | BSX |
|---|---|---|
| Market Cap | $11.36B | $65.44B |
| P/E (TTM) | 38.15 | 18.42 |
| Forward P/E | 19.87 | 14.88 |
| P/S | 3.83 | 4.04 |
| P/B | 8.91 | 2.95 |
| EV/EBITDA | 19.65 | 16.91 |
| Dividend Yield | — | — |
| Profit Margin | 10.44% | 17.29% |
| Gross Margin | 71.63% | 69.01% |
| Operating Margin | 17.50% | 19.78% |
| Revenue Growth (YoY) | +33.87% | +11.58% |
| FCF Yield | 3.49% | 3.96% |
| Debt / Equity | 72.79 | 41.78 |
| Current Ratio | 2.49 | 1.90 |
Which is better: Insulet Corporation or Boston Scientific Corporation?
- ✓Larger by market cap: Boston Scientific Corporation
- ✓Cheaper valuation (lower P/E): Boston Scientific Corporation
- ✓More profitable (net margin): Boston Scientific Corporation
- ✓Faster revenue growth: Insulet Corporation
- ✓Higher free-cash-flow yield: Boston Scientific Corporation
Across 12 available metrics, Boston Scientific Corporation leads 8–4.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.